602 related articles for article (PubMed ID: 19249675)
1. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
Loges S; Mazzone M; Hohensinner P; Carmeliet P
Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
[TBL] [Abstract][Full Text] [Related]
2. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to antiangiogenesis therapy.
Azam F; Mehta S; Harris AL
Eur J Cancer; 2010 May; 46(8):1323-32. PubMed ID: 20236818
[TBL] [Abstract][Full Text] [Related]
4. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
[TBL] [Abstract][Full Text] [Related]
5. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
[TBL] [Abstract][Full Text] [Related]
6. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage.
Koh YJ; Kim HZ; Hwang SI; Lee JE; Oh N; Jung K; Kim M; Kim KE; Kim H; Lim NK; Jeon CJ; Lee GM; Jeon BH; Nam DH; Sung HK; Nagy A; Yoo OJ; Koh GY
Cancer Cell; 2010 Aug; 18(2):171-84. PubMed ID: 20708158
[TBL] [Abstract][Full Text] [Related]
7. Platelets and cancer: implications for antiangiogenic therapy.
Trikha M; Nakada MT
Semin Thromb Hemost; 2002 Feb; 28(1):39-44. PubMed ID: 11885024
[TBL] [Abstract][Full Text] [Related]
8. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
Crawford Y; Ferrara N
Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
[TBL] [Abstract][Full Text] [Related]
9. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
Ellis LM; Hicklin DJ
Clin Cancer Res; 2008 Oct; 14(20):6371-5. PubMed ID: 18927275
[TBL] [Abstract][Full Text] [Related]
10. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
Epstein RJ
Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic cancer therapy.
Cao Y
Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
[TBL] [Abstract][Full Text] [Related]
12. VEGF inhibition: insights from preclinical and clinical studies.
Crawford Y; Ferrara N
Cell Tissue Res; 2009 Jan; 335(1):261-9. PubMed ID: 18766380
[TBL] [Abstract][Full Text] [Related]
13. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
Ribatti D
Cancer Treat Rev; 2011 Aug; 37(5):344-52. PubMed ID: 21435792
[TBL] [Abstract][Full Text] [Related]
14. Why do tumors become resistant to antiangiogenesis drugs?
Schmidt C
J Natl Cancer Inst; 2009 Nov; 101(22):1530-2. PubMed ID: 19880813
[No Abstract] [Full Text] [Related]
15. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy.
Sato Y
Cancer Sci; 2011 Jul; 102(7):1253-6. PubMed ID: 21401807
[TBL] [Abstract][Full Text] [Related]
16. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use].
Plavetić ND; Letilović T; Vrbanec D
Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of angiogenesis and the angiogenesis/invasion shift.
Bikfalvi A; Moenner M; Javerzat S; North S; Hagedorn M
Biochem Soc Trans; 2011 Dec; 39(6):1560-4. PubMed ID: 22103487
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
19. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
20. Tumor angiogenesis in melanoma.
Marneros AG
Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
